Evidence map›Paper›PMID 28919119›Full record

ArticleLancet (London, England)2017

Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.

GBD 2016 Risk Factors Collaborators

Erratum issued 7 registry-linked trialsAbstract read
In one paragraph

Article in Lancet (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 7 registered trials, which are not on this map. Cited by 1,147 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,147citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03394963 completednot on this mapstarted 2019, after this paper: background citation

Scientific Foundations for Developing and Validating Food-based Dietary Guidelines and a Healthy Eating Index for Ethiopia

TypeobservationalSponsorEthiopian Public Health InstituteRan2019 to 2022Enrolled500ConditionsHealthyArmsFood-based dietary guidelines for healthier diet
NCT04407962 nacompletednot on this mapstarted 2020, after this paper: background citation

PUSHME (Primary Care USage of Health Promoting Messages): A Text Message-based Intervention in Primary Care Patients With Hypertension: a Randomized Controlled Trial

TypeinterventionalSponsorLund UniversityRan2020 to 2023Enrolled400ConditionsHypertension, Cardiovascular Risk FactorArmsSMS group
NCT05563740 nacompletednot on this mapstarted 2020, after this paper: background citation

Assisted vs Unassisted Domiciliary Alcohol Detoxification: A Randomised Control Trial

TypeinterventionalSponsorDr Sneha B SureshRan2020 to 2020Enrolled100ConditionsAlcohol Use DisorderArmsPsychosocial
NCT06261385 nacompletednot on this mapstarted 2024, after this paper: background citation

Development of Typology-based Smoking Relapse Prevention: A Q-methodology and a Pilot Randomized Controlled Trial

TypeinterventionalSponsorThe University of Hong KongRan2024 to 2025Enrolled100ConditionsSmoking CessationArmstypology-based intervention, Routine Treatment
NCT06364930 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

Sodium-glucose Co-transporter-2 Inhibitor (SGLT2i) to Prevent of Liver Complications in Patients With Chronic Hepatitis B and Diabetes Mellitus: a Double-blind, Randomised, Placebo-controlled Trial

TypeinterventionalSponsorChinese University of Hong KongRan2024 to 2031Enrolled412ConditionsChronic Hepatitis BArmsDapagliflozin 10mg Tab, Placebo 10mg Tab
NCT06447974 narecruitingnot on this mapstarted 2025, after this paper: background citation

The Barts Charity Children's Environmental Health Clinic

TypeinterventionalSponsorQueen Mary University of LondonRan2025 to 2027Enrolled200ConditionsEnvironmental Exposure, Health Behavior, Asthma in Children, Environmental IllnessArmsExposure mitigations
NCT06571942 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Effect of the Inhaled Triple Therapies Over the Small Airway in Patients With Chronic Obstructive Pulmonary Disease or Chronic Bronchitis Without Obstruction Secondary to Biomass Exposure: Randomized Controlled Clinical Trial Phase IV

TypeinterventionalSponsorNational Institute of Respiratory Diseases, MexicoRan2023 to 2025Enrolled128ConditionsCOPD Bronchitis, Pollution Related Respiratory DisorderArmsVilanterol / Umeclidinium (25/62.5 mcg), Fluthicasone / Vilanterol / Umeclidinium (100/25/62.5 mcg), Beclomethasone / Formoterol / Glycopyrronyum 100/6/12.5 mcg, Budesonide / Formoterol / Glycopyrronyum 160/4.8/7.2 mcg
3 · Its place in the literature

Who cites it

1,147 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. The Efficacy of Oral Vitamin Supplementation in Dry Eye Disease: A Systematic Review.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Associations of exposure to PMBMC public health · 2025
    Pooled it
  6. Pooled it
  7. Pooled it
  8. Combined lifestyle factors on mortality and cardiovascular disease among cancer survivors: a systematic review and meta-analysis of cohort studies.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024
    Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,087 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

GBD 2016 Risk Factors Collaborators

Funding

HRS Yrs29-34: Y33 SSA CoFundingU01AG009740 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jessica Faul, KENNETH M LANGA · 1990 to 2026
$555.8M
Wave IV Data CollectionP01HD031921 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARRIS, KATHLEEN MULLAN · 1994 to 2020
$86.1M
Integrting Information About Aging SurveysR01AG030153 · NIA · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Sara Adar, Alden L. Gross · 2007 to 2026
$41.7M
"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8M
Stroke Investigative Research & Educational Network (SIREN)U54HG007479 · NHGRI · COLLEGE OF MEDICINE, UNIVERSITY OF IBADAN · PI OVBIAGELE, BRUCE, OWOLABI, MAYOWA OJO · 2013 to 2017
$4.2M
Long term outcomes of therapy in women initiated on lifelong ART because of pregnancy in DR CongoR01HD087993 · NICHD · OHIO STATE UNIVERSITY · PI BABAKAZO, PELAGIE DIAMBALULA, YOTEBIENG, MARCEL · 2016 to 2020
$3.1M
Training Tanzanian Researchers for HIV/AIDS Implementation ScienceD43TW009775 · FIC · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Wafaie W Fawzi, Christopher Sudfeld · 2015 to 2026
$3.0M
New Methods for the design and evaluation of large HIV prevention interventionsR01AI112339 · NIAID · YALE UNIVERSITY · PI SPIEGELMAN, DONNA L · 2014 to 2017
$2.7M
Causal Pathways to population health impact of HIV antiretroviral treatmentR01HD084233 · NICHD · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2015 to 2021
$2.3M
Can HIV Hot-Spots be eradicated? An intervention to decrease HIV transmission to young women in rural KwaZulu-Natal South AfricaR01AI124389 · NIAID · UNIVERSITY OF KWAZULU-NATAL · PI BARNIGHAUSEN, TILL, TANSER, FRANK COURTENEY · 2016 to 2020
$2.1M
Health and Retirement Survey for IndiaR21AG032572 · NIA · HARVARD SCHOOL OF PUBLIC HEALTH · PI BLOOM, DAVID E · 2008 to 2009
$467k
Archiving & Creating User Friendly Data: the Longitudinal Aging Survey in IndiaR03AG043052 · NIA · RAND CORPORATION · PI LEE, JINKOOK · 2012 to 2012
$95k
Chief Scientist Office SCAF/15/02Chief Scientist Office SPHSU13Chief Scientist Office SPHSU15Department of Health CDF-2011-04-048FIC NIH HHS D43 TW009775Medical Research Council G0400491Medical Research Council MC_U147585819Medical Research Council MC_U147585824Medical Research Council MC_U147585827Medical Research Council MC_UP_A620_1014Medical Research Council MC_UP_A620_1015Medical Research Council MC_UU_12011/1Medical Research Council MC_UU_12011/2Medical Research Council MC_UU_12017/13Medical Research Council MC_UU_12017/15Medical Research Council MR/K013351/1NHGRI NIH HHS U54 HG007479NIAID NIH HHS R01 AI112339NIAID NIH HHS R01 AI124389NIAID NIH HHS U01 AI096299NIA NIH HHS HHSN271201300071CNIA NIH HHS R01 AG030153NIA NIH HHS R03 AG043052NIA NIH HHS R21 AG032572NIA NIH HHS U01 AG009740NICHD NIH HHS P01 HD031921NICHD NIH HHS R01 HD084233NICHD NIH HHS R01 HD087993Wellcome Trust 201900Wellcome Trust 201900/Z/16/Z
6 · The paper itself

Abstract

backgroundThe Global Burden of Diseases, Injuries, and Risk Factors Study 2016 (GBD 2016) provides a comprehensive assessment of risk factor exposure and attributable burden of disease. By providing estimates over a long time series, this study can monitor risk exposure trends critical to health surveillance and inform policy debates on the importance of addressing risks in context.

methodsWe used the comparative risk assessment framework developed for previous iterations of GBD to estimate levels and trends in exposure, attributable deaths, and attributable disability-adjusted life-years (DALYs), by age group, sex, year, and location for 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks from 1990 to 2016. This study included 481 risk-outcome pairs that met the GBD study criteria for convincing or probable evidence of causation. We extracted relative risk (RR) and exposure estimates from 22 717 randomised controlled trials, cohorts, pooled cohorts, household surveys, census data, satellite data, and other sources, according to the GBD 2016 source counting methods. Using the counterfactual scenario of theoretical minimum risk exposure level (TMREL), we estimated the portion of deaths and DALYs that could be attributed to a given risk. Finally, we explored four drivers of trends in attributable burden: population growth, population ageing, trends in risk exposure, and all other factors combined.

findingsSince 1990, exposure increased significantly for 30 risks, did not change significantly for four risks, and decreased significantly for 31 risks. Among risks that are leading causes of burden of disease, child growth failure and household air pollution showed the most significant declines, while metabolic risks, such as body-mass index and high fasting plasma glucose, showed significant increases. In 2016, at Level 3 of the hierarchy, the three leading risk factors in terms of attributable DALYs at the global level for men were smoking (124·1 million DALYs [95% UI 111·2 million to 137·0 million]), high systolic blood pressure (122·2 million DALYs [110·3 million to 133·3 million], and low birthweight and short gestation (83·0 million DALYs [78·3 million to 87·7 million]), and for women, were high systolic blood pressure (89·9 million DALYs [80·9 million to 98·2 million]), high body-mass index (64·8 million DALYs [44·4 million to 87·6 million]), and high fasting plasma glucose (63·8 million DALYs [53·2 million to 76·3 million]). In 2016 in 113 countries, the leading risk factor in terms of attributable DALYs was a metabolic risk factor. Smoking remained among the leading five risk factors for DALYs for 109 countries, while low birthweight and short gestation was the leading risk factor for DALYs in 38 countries, particularly in sub-Saharan Africa and South Asia. In terms of important drivers of change in trends of burden attributable to risk factors, between 2006 and 2016 exposure to risks explains an 9·3% (6·9-11·6) decline in deaths and a 10·8% (8·3-13·1) decrease in DALYs at the global level, while population ageing accounts for 14·9% (12·7-17·5) of deaths and 6·2% (3·9-8·7) of DALYs, and population growth for 12·4% (10·1-14·9) of deaths and 12·4% (10·1-14·9) of DALYs. The largest contribution of trends in risk exposure to disease burden is seen between ages 1 year and 4 years, where a decline of 27·3% (24·9-29·7) of the change in DALYs between 2006 and 2016 can be attributed to declines in exposure to risks.

interpretationIncreasingly detailed understanding of the trends in risk exposure and the RRs for each risk-outcome pair provide insights into both the magnitude of health loss attributable to risks and how modification of risk exposure has contributed to health trends. Metabolic risks warrant particular policy attention, due to their large contribution to global disease burden, increasing trends, and variable patterns across countries at the same level of development. GBD 2016 findings show that, while it has huge potential to improve health, risk modification has played a relatively small part in the past decade.

fundingThe Bill & Melinda Gates Foundation, Bloomberg Philanthropies.

Indexed as

AdolescentAdultAgedAged, 80 and overAir PollutionBody Mass IndexCause of DeathChildChild, PreschoolCommunicable DiseasesEnvironmental HealthFemaleGlobal Burden of DiseaseHumansInfantInfant, Newborn

Identifiers

PMID28919119
PMCPMC5614451

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

and 1 more above

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.